Nymox Pharmaceutical (NYMX) Getting Somewhat Favorable Press Coverage, Report Finds
Media headlines about Nymox Pharmaceutical (NASDAQ:NYMX) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Nymox Pharmaceutical earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.9580984993737 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Nymox Pharmaceutical (NYMX) traded up $0.10 during midday trading on Friday, reaching $3.39. The company had a trading volume of 85,098 shares, compared to its average volume of 87,370. The firm has a market cap of $180.40, a PE ratio of -14.12 and a beta of 0.83. Nymox Pharmaceutical has a 12 month low of $2.80 and a 12 month high of $5.10. The company has a quick ratio of 1.42, a current ratio of 1.44 and a debt-to-equity ratio of 61.64.
TRADEMARK VIOLATION NOTICE: “Nymox Pharmaceutical (NYMX) Getting Somewhat Favorable Press Coverage, Report Finds” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/nymox-pharmaceutical-nymx-getting-somewhat-favorable-press-coverage-report-finds/1806074.html.
Nymox Pharmaceutical Company Profile
Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with Analyst Ratings Network's FREE daily email newsletter.